211 related articles for article (PubMed ID: 29454317)
21. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
22. Secondary stimulation from Bacillus Calmette-Guérin induced macrophages induce nitric oxide independent cell-death in bladder cancer cells.
Thiel T; Ryk C; Chatzakos V; Hallén Grufman K; Bavand-Chobot N; Flygare J; Wiklund NP; de Verdier PJ
Cancer Lett; 2014 Jun; 348(1-2):119-25. PubMed ID: 24657658
[TBL] [Abstract][Full Text] [Related]
23. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
24. Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans.
Giovannone N; Antonopoulos A; Liang J; Geddes Sweeney J; Kudelka MR; King SL; Lee GS; Cummings RD; Dell A; Barthel SR; Widlund HR; Haslam SM; Dimitroff CJ
Front Immunol; 2018; 9():2857. PubMed ID: 30619255
[TBL] [Abstract][Full Text] [Related]
25. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
[TBL] [Abstract][Full Text] [Related]
26. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
27. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
28. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Urol Oncol; 2010; 28(3):285-9. PubMed ID: 18976938
[TBL] [Abstract][Full Text] [Related]
29. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
30. Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer.
Zhong W; Wang B; Yu H; Lin J; Xia K; Hou W; Yang M; Chen J; Yang M; Wang X; Huang J; Lin T
Oncoimmunology; 2020 Jun; 9(1):1776060. PubMed ID: 32923138
[TBL] [Abstract][Full Text] [Related]
31. A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy.
Kim SK; Park SH; Kim YU; Byun YJ; Piao XM; Jeong P; Kim K; Lee HY; Seo SP; Kang HW; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Kim WJ; Kim SY; Yun SJ
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535616
[TBL] [Abstract][Full Text] [Related]
32. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
33. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
34. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.
Liem EIML; Baard J; Cauberg ECC; Bus MTJ; de Bruin DM; Laguna Pes MP; de la Rosette JJMCH; de Reijke TM
Med Oncol; 2017 Sep; 34(10):172. PubMed ID: 28866819
[TBL] [Abstract][Full Text] [Related]
35. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Kim HS; Seo HK
Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
[TBL] [Abstract][Full Text] [Related]
36. Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.
Luo Y; Henning J; O'Donnell MA
Clin Dev Immunol; 2011; 2011():728930. PubMed ID: 21941579
[TBL] [Abstract][Full Text] [Related]
37. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
[TBL] [Abstract][Full Text] [Related]
38. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.
Bevers RF; Kurth KH; Schamhart DH
Br J Cancer; 2004 Aug; 91(4):607-12. PubMed ID: 15266312
[TBL] [Abstract][Full Text] [Related]
39. Baseline Cytokine Profiles of Tuberculin-Specific CD4
Jallad S; Thomas P; Newport MJ; Kern F
Cancer Immunol Res; 2018 Oct; 6(10):1212-1219. PubMed ID: 30120103
[TBL] [Abstract][Full Text] [Related]
40. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]